EIDD-2801

DRUG2 trials

Sponsors

Ridgeback Biotherapeutics, LP

Conditions

CoronavirusSARS-CoV 2

Phase 1

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

CompletedNCT04392219

Ridgeback Biotherapeutics, LPCoronavirus

Start: 2020-04-10End: 2020-08-11Updated: 2021-07-19

Phase 2

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

CompletedNCT04405739

Ridgeback Biotherapeutics, LPSARS-CoV 2

Start: 2020-06-16End: 2022-02-21Updated: 2023-03-23

Related Papers

The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective

Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice2022-11-141 citations

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Antibiotics2021-10-2385 citations

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Journal of Antimicrobial Chemotherapy2021-08-18111 citations

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.

2020-12-03308 citations